Get started
CRISPR THERADRNCRISPR THERADRNCRISPR THERADRN

CRISPR THERADRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

C2RS34 trade ideas

CRSP short trade updated chartHere is the updated chart on CRSP short trade I posted on January 14th. It's been down 23% since the date it was posted. So far so good. First target was hit today and managed to keep above as I have expected. I expect more downside in days to come. XBI sector can break down anytime too now. Literally one red day will do. My next target is the bottom of the channel colored yellow. Once the selling gets momentum, it will be pretty swift downward move. Definitely can't fall a sleep behind the wheel right now in this market. Have a good trades everyone, T.
NASDAQ:CRSPShort
by TK0421
THE EXCITEMENT AROUND THIS SECTOR IS REALDescription CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland. Corporate Governance CRISPR Therapeutics AG’s ISS Governance QualityScore as of December 1, 2020 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 3; Compensation: 10. Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
NASDAQ:CRSPLong
by clarkehimself
High probability swing short set up on CRSPHere is my short case on CRSP: - at the top of trading channel started since Feb 2020 - over bought reading on RSI - both PPO and RSI shows very clear divergence high Starting building a position as it hits the top of the channel and scale in as it moves down. Impulsive break of the wedge should move it down to the support at $161. Reaction will be likely, consolidation or a minor bounce. Then, if it gets taken down, then moving down to the bottom of the channel which intersects with $145.80 horizontal support. If that breaks, it's going way lower since $110 and $131 area are pretty thin so the move will be probably pretty swift.
NASDAQ:CRSPShort
by TK0421
5